Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Quince Therapeutics (QNCX) Stock Forecast & Price Target

Quince Therapeutics logo
$1.62
+0.31 (+23.66%)
(As of 10/31/2024 ET)

Quince Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
0
Buy
3

Based on 3 Wall Street analysts who have issued ratings for Quince Therapeutics in the last 12 months, the stock has a consensus rating of "Strong Buy." Out of the 3 analysts, 1 has given a buy rating, and 2 have given a strong buy rating for QNCX.

Consensus Price Target

$11.00
579.01% Upside
According to the 3 analysts' twelve-month price targets for Quince Therapeutics, the average price target is $11.00. The highest price target for QNCX is $11.00, while the lowest price target for QNCX is $11.00. The average price target represents a forecasted upside of 579.01% from the current price of $1.62.

QNCX Analyst Ratings Over Time

TypeCurrent Forecast
11/2/23 to 11/1/24
1 Month Ago
10/3/23 to 10/2/24
3 Months Ago
8/4/23 to 8/3/24
1 Year Ago
11/2/22 to 11/2/23
Strong Buy
2 Strong Buy rating(s)
N/A N/A N/A
Buy
1 Buy rating(s)
N/A N/A N/A
Hold
0 Hold rating(s)
N/A N/A N/A
Sell
0 Sell rating(s)
N/A N/A N/A
Consensus Price Target$11.00N/AN/AN/A
Forecasted Upside579.01% UpsideN/AN/AN/A
Consensus Rating
Strong Buy
N/A
N/A
N/A

QNCX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

QNCX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Quince Therapeutics Stock vs. The Competition

TypeQuince TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
3.67
2.79
2.50
Consensus RatingStrong BuyModerate BuyHold
Predicted Upside579.01% Upside16,656.06% Upside10.64% Upside
News Sentiment Rating
Neutral News

See Recent QNCX News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/29/2024RODMAN&RENSHAW
0 of 5 stars
E. Piros
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
10/29/2024Rodman & Renshaw
1 of 5 stars
 Initiated CoverageBuy$11.00+1,009.31%
10/22/2024EF Hutton Acquisition Co. I
1 of 5 stars
J. Kolbert
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:24 AM ET.


QNCX Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Quince Therapeutics is $11.00, with a high forecast of $11.00 and a low forecast of $11.00.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quince Therapeutics in the last twelve months. There is currently 1 buy rating and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "strong buy" QNCX shares.

According to analysts, Quince Therapeutics's stock has a predicted upside of 579.01% based on their 12-month stock forecasts.

Over the previous 90 days, Quince Therapeutics's stock had 2 upgrades by analysts.

Quince Therapeutics has been rated by research analysts at EF Hutton Acquisition Co. I, Rodman & Renshaw, and RODMAN&RENSHAW in the past 90 days.

Analysts like Quince Therapeutics more than other "medical" companies. The consensus rating for Quince Therapeutics is Strong Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how QNCX compares to other companies.


This page (NASDAQ:QNCX) was last updated on 11/1/2024 by MarketBeat.com Staff
From Our Partners